Literature DB >> 26352732

Scleroderma renal crisis.

Marie Hudson1.   

Abstract

PURPOSE OF REVIEW: There are important knowledge gaps concerning scleroderma renal crisis (SRC), in large part because its rarity has hampered research. Many studies to date share limitations, in particular small samples, prevalent cases, and retrospective study designs. This review features some of the most recent studies that attempt to shed new insights into SRC while trying to overcome those limitations. RECENT
FINDINGS: The most important recent progress in the understanding of the pathophysiology of SRC includes identification of novel genetic and serological biomarkers. Outcomes of SRC remain poor and there are also ongoing efforts to identify novel therapeutic strategies, in particular targeting the endothelin-1 pathway.
SUMMARY: Meaningful improvement in outcomes of SRC will be predicated on greater understanding of the underlying mechanisms of disease and identification of novel therapeutic and preventive strategies. Some efforts are ongoing but ultimately, international cooperation will be necessary to achieve this for a rare complication of a rare disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26352732     DOI: 10.1097/BOR.0000000000000221

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  5 in total

1.  Glomerulonephritis and Coombs-positive hemolytic anemia mimicking scleroderma renal crisis in an overlap of systemic lupus erythematosus and diffuse systemic sclerosis.

Authors:  Ali Taylan; Emel Tekin; Bahar Engin
Journal:  Rheumatol Int       Date:  2019-11-07       Impact factor: 2.631

2.  Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.

Authors:  Lorinda Chung; Cathie Spino; Richard McLain; Sindhu R Johnson; Christopher P Denton; Jerry A Molitor; Virginia D Steen; Robert Lafyatis; Robert W Simms; Suzanne Kafaja; Tracy M Frech; Vivien Hsu; Robyn T Domsic; Janet E Pope; Jessica K Gordon; Maureen D Mayes; Nora Sandorfi; Faye N Hant; Elana J Bernstein; Soumya Chatterjee; Flavia V Castelino; Ali Ajam; Yannick Allanore; Marco Matucci-Cerinic; Michael L Whitfield; Oliver Distler; Ora Singer; Amber Young; Vivek Nagaraja; David A Fox; Daniel E Furst; Dinesh Khanna
Journal:  Lancet Rheumatol       Date:  2020-10-19

3.  Acute renal failure in systemic sclerosis revealing Goodpasture syndrome: "All that glitters is not scleroderma renal crisis".

Authors:  Renaud Felten; Benoît Nespola; Emmanuel Chatelus; Laurent Arnaud; Jacques-Eric Gottenberg; Matthieu Canuet; Eric Prinz; Joëlle Goetz; Jean Sibilia
Journal:  J Scleroderma Relat Disord       Date:  2019-04-02

Review 4.  Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease.

Authors:  Radko Komers; Horacio Plotkin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-03-23       Impact factor: 3.619

Review 5.  Vascular Remodelling and Mesenchymal Transition in Systemic Sclerosis.

Authors:  Pier Andrea Nicolosi; Enrico Tombetti; Norma Maugeri; Patrizia Rovere-Querini; Silvia Brunelli; Angelo A Manfredi
Journal:  Stem Cells Int       Date:  2016-03-16       Impact factor: 5.443

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.